2004
DOI: 10.1590/s1415-47572004000100019
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin levels, thereby decreasing the severity of SCD. However, high doses or prolonged treatment with hydroxyurea can be cytotoxic or genotoxic for these patients, with an increased risk of developing acute leukemia. This danger can be avoided by monitoring the lymp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
5
0
1

Year Published

2006
2006
2017
2017

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 10 publications
1
5
0
1
Order By: Relevance
“…A lack of genotoxicity in lymphocytes was also found in in vitro studies carried out by our group after HU treatment of healthy subjects and SCA patients [22,23]. These results support the hypothesis that HU has no direct effect on DNA.…”
Section: Discussionsupporting
confidence: 83%
“…A lack of genotoxicity in lymphocytes was also found in in vitro studies carried out by our group after HU treatment of healthy subjects and SCA patients [22,23]. These results support the hypothesis that HU has no direct effect on DNA.…”
Section: Discussionsupporting
confidence: 83%
“…Others state the absence of genotoxic effects of normal doses of HU (25 mg/kg/day), because they did not find significant differences in chromosomal aberrations between treated Hb SS patients and normal volunteers (30,31).…”
Section: Discussionmentioning
confidence: 99%
“…In contrast, for hydroxyurea no EC value could be calculated ( Table 2). This nil response might be caused by the indirect action of the antineoplastic agent that induces cell cycle arrests by a non-DNA-interactive mechanism (16), an effect beyond the 4-h observation period (test criteria, no full doubling).…”
Section: Discussionmentioning
confidence: 99%